Prerpints.org logo
Preprint
Review

Hemodynamic Melody of Postnatal Cardiac and Pulmonary Development in Children with Congenital Heart Diseases

Altmetrics

Downloads

125

Views

85

Comments

0

A peer-reviewed article of this preprint also exists.

This version is not peer-reviewed

Submitted:

23 February 2024

Posted:

26 February 2024

You are already at the latest version

Alerts
Abstract
Hemodynamics is the eternal theme of the circulatory system. Abnormal hemodynamics and cardiac and pulmonary development intertwine to form the most important features of children with congenital heart diseases (CHDs), thus determining these children’s long-term quality of life. However, due to the lack of neonatal rodent models of CHDs, it is unclear how CHD-associated hemodynamics shape postnatal cardiac and pulmonary development. Here, we review the varieties of hemodynamic abnormalities that exist in children with CHDs, the recently developed neonatal rodent models of CHDs, and the inspirations these models have brought us in the areas of cardiomyocyte proliferation and maturation, and in alveolar development. Furthermore, current limitations, future directions, and clinical decision-making based on these inspirations are highlighted. Understanding how CHD-associated hemodynamic scenarios shape postnatal heart and lung development may provide a novel path to improving the long-term quality of life of children with CHDs, transplantation of stem cell–derived cardiomyocytes, and cardiac regeneration.
Keywords: 
Subject: Medicine and Pharmacology  -   Cardiac and Cardiovascular Systems

1. Introduction

Since Harvey’s discovery of the circulatory system in 1628, it has been recognized that the primary function of the circulatory system is to provide organs, including the heart and lungs, with well-oxygenated blood and nutrients, as well as to transport all types of harmful metabolites [1,2]. The hemodynamics resulting from blood flowing in the circulatory system inevitably becomes the eternal theme of the circulatory system [1,2]. Insufficient embryonic volume load is one of the main causes of left ventricular dysplasia, while adult volume overload (VO) or pressure overload (PO) leads to cardiac failure [3,4,5,6,7]. However, pediatric hearts and lungs are in a stage of active development. For example, 90% of alveoli form between the ages of 0 and 7 years, and there is an extensive cardiomyocyte maturation transition [8,9]. Hemodynamic modifications of embryonic or adult hearts and lungs are well established [3,4,5,6,7], but leave a vacuum to be filled of our understanding of the hemodynamic shaping of pediatric hearts and lungs.
Congenital heart diseases (CHDs) represent the most prevalent birth defect in the world [10,11]. With the progress in pediatric cardiac surgery, cardiology, and cardiac intensive care, most simple CHDs can be corrected, and the overall mortality shows a significant downward trend. However, the mortality of complex CHDs, such as hypoplastic left heart syndrome, Ebstein anomaly (EA), and tetralogy of Fallot (TOF), is still very high. Most of these cannot be physiologically corrected, leaving residual hemodynamic abnormalities, such as cardiac volume overload (VO), pressure overload (PO), pulmonary congestion, and reduced pulmonary blood flow (RPF), and therefore hemodynamic abnormalities dominate postnatal cardiac and pulmonary development in children with CHDs [12,13,14,15,16,17]. As a result, the long-term life quality of children with complex CHDs is poor, with significantly reduced exercise capacity and impaired cardiac performance, and some children ultimately require heart or lung transplantation [18,19].
In addition, cardiovascular therapies that are very effective in adults have limited effectiveness or even cause harm when treating infants and young children [20,21]. A possible reason underlying this phenomenon is that the extremely small size of a neonatal mouse heart challenges the creation of neonatal surgical mouse models of cardiovascular diseases. Consequently, clinicians or scientists generally use adult mouse models to explore mechanisms and pathophysiology and to obtain targets for pediatric cardiovascular diseases.
Here we reviewed the abnormal hemodynamics in children with CHDs and the recently developed neonatal surgeries for producing CHD-hemodynamic-associated animal models, which include neonatal aortic and inferior vena cava fistula (nACF) surgery, neonatal pulmonary artery banding (nPAB) surgery, neonatal pulmonary vein banding (nPVB) surgery, and neonatal transverse aortic constriction (nTAC) surgery [22,23,24,25,26,27,28,29,30,31,32,33]. nACF produces atrial and ventricular VO and pulmonary congestion; nPAB produces right ventricular (RV) PO and RPF; nPVB produces pulmonary vein stenosis (PVS), one of the most challenging issues of pediatric CHDs [34]; and nTAC produces left ventricular (LV) PO. These neonatal surgeries greatly inspire our understanding of the hemodynamic melody of postnatal cardiac and pulmonary development, such as cardiomyocyte proliferation and maturation, and pulmonary dysplasia.

2. Abnormal Hemodynamics in Children with CHD

2.1. Abnormal Hemodynamics in Ventricles

CHD usually leads to ventricular VO and PO, specifically RV VO, LV VO, RV PO, and LV PO. Table 1 summarizes each type of abnormal hemodynamic and its corresponding CHDs.
There are three types of CHDs that can result in RV VO. The first type is CHD with a left-to-right shunt, which includes atrial septal defect (ASD), patent ductus arteriosus (PDA), partial anomalous pulmonary vein drainage (PAPVD), atrioventricular septal defect (AVSD), and ventricular septal defect (VSD) [35,36,37,38,39]. The second type is right heart valve regurgitation-associated CHDs, which include tricuspid regurgitation (TR), EA, pulmonary regurgitation, pulmonary valve insufficiency (PVI), and TOF after patch enlargement of the RV outflow tract correction [40,41,42,43,44]. The third includes advanced pulmonary hypertension (PH), increased returning blood (e.g., in thyrotoxicosis), and functional univentricular conditions (e.g., hypoplastic left heart syndrome and Fontan surgery) [45,46,47].
Right-to-left shunting and left heart valvular regurgitation can lead to LV VO. Right-to-left shunting-associated CHDs include ASD with tricuspid stenosis (TS) or RV outflow obstruction (RVOT)[48]. These defects result in a high pressure in the right atrium compared to the left atrium, leading to a right-to-left shunt. Left heart valvular regurgitation includes congenital mitral regurgitation (CMR), acquired mitral regurgitation (rheumatic or calcific mitral valve), aortic valve calcification, and bicuspid aortic valve (BAV) [49,50,51]. In addition, increased venous return can lead to LV VO.
PH, left cardiac defects that cause PH at later stages, and RVOT obstructive diseases may cause RV PO. CHDs that cause PH include PVS, large VSD, and PDA [34,36,39,52]. Large VSD and PDA lead to increased pulmonary blood flow, resulting in pulmonary congestion and small vessel remodeling, which in turn causes PH. CHD with a left cardiac defect that causes PH includes mitral or aortic stenosis (MS or AS), and coarctation/interruption of the aortic arch (CAA/IAA) [50,51,53]. CHDs with RVOT obstruction includes TOF, isolated pulmonary artery obstruction or embolism, pulmonary artery stenosis (PAS), and pulmonary valve stenosis (PS) [54,55,56,57].
Hypertension and left ventricular outflow tract (LVOT) obstruction leads to LV PO. Hypertension is uncommon in children. CHD with LVOT obstruction includes BAV, CAA/IAA, mitral or aortic stenosis, and hypertrophic cardiomyopathy [50,51,53,58].
It is evident from Table 1 that various hemodynamic abnormalities, including both ventricular VO and PO, usually coexist in the same type of CHD. In addition, these hemodynamic abnormalities are closely associated with the disease progression, and sometimes one type of abnormal hemodynamic abnormality dominates a particular stage of disease progression. The extent of VO and PO often determines the performance of the RV and LV, as well as surgical approaches and the prognosis of children with CHDs. Therefore, gaining a comprehensive understanding of how VO and PO shape postnatal cardiac development may help establish a theoretical foundation for enhancing the quality of life in children with CHD.

2.2. Abnormal Hemodynamics in Lungs

A left-to-right shunt or increased venous return will induce increased pulmonary blood flow (IPF), which leads to pulmonary congestion, ultimately resulting in pulmonary hypertension and congestive heart failure. RVOT obstruction, such as TOF and PS, results in RPF, which leads to pulmonary dysplasia and reduced exercise endurance, and renders patients less susceptible to COVID-19 infection [25,29,59,60]. A deeper understanding of the mechanisms by which IPF and RPF regulate postnatal lung development may help improve lung function and exercise capacity in children with CHD.
PVS is another deadly CHD [28,34]. Stenosis of the pulmonary vein leads to remodeling of small pulmonary vessels, which in turn leads to PH, and ultimately right heart failure occurs. Despite advancements in surgical techniques, interventional procedures, and postoperative monitoring, the prognosis for children with PVS remains unfavorable, with 60% of children with PVS dying within 2 years after diagnosis [34]. Moreover, due to stenosis, there may be oozing blood upstream of the pulmonary vessels, giving rise to hemoptysis and pulmonary infections, which further deteriorate the prognosis of children with PVS. Understanding how and why PVS occurs is crucial to treat children with PVS.

3. Immature Hearts and Lungs in Children

3.1. Immature Hearts in Children

Unlike adult mature hearts and lungs, children’s hearts and lungs are immature and at an active stage of development [8,12].
To meet the physiological demands of pumping blood at adulthood, there are three main characteristic that immature cardiomyocytes need to develop (Figure 1) [8,61,62,63,64,65,66,67]: (1) sarcomere maturation, which includes sarcomere component maturation (an Myh7 to Myh6 and TnI1 to TnI3 switch), and arrangement maturation (disordered and irregular arrangement switched to a rod-like and orderly arrangement); (2) metabolism maturation, which is a shift from anaerobic glycolysis to oxidative phosphorylation due to mitochondrial maturation, with an increase in the number of mitochondrial and their ridges, as well as a closer proximity of mitochondria to sarcomeres; and (3) electrophysiological maturation, in which transverse tubules (T-tubules) form, with a gradually increased density and integrity, and are accompanied by a significant improvement in calcium handling and excitation-contraction coupling. Failure of cardiomyocyte maturation results in arrhythmias and heart failure.

3.2. Immature Lungs in Children

There are five developmental stages of human lungs (Figure 2) [68,69,70,71]: (1) Embryonic stage (pulmonary bud stage): Occurring between the third and sixth weeks of gestation, this stage marks the appearance of precursor cells and epidermal cells known as pulmonary buds. (2) Pseudoglandular stage (bronchial stage): Taking place between the sixth and 16th weeks of gestation, this stage is characterized by bronchial formation. The pulmonary buds proliferate and migrate to the visceral mesenchyme, forming airways and peripheral acinar buds, eventually developing into alveoli. (3) Tubular phase (alveolar tubular phase): This stage occurs from 16–26 weeks of gestation and involves the differentiation of intra-airway epithelial cells, including basal cells, cupped cells, ciliated cells, and other secretory cells. (4) Vesicular phase (terminal vesicular phase): Spanning from 26–36 weeks of gestation, the differentiation of peripheral glandular alveoli characterizes this phase, including cubic type 2 alveolar (AT2) cells and squamous type 1 alveolar (AT1) cells. At this stage, alveoli gradually expand and are covered by AT1 cells, and AT2 cells differentiate to produce alveolar surfactant. (5) Alveolar phase: This phase, which extends from 36 weeks of gestation to adolescence, is the main stage of alveolar formation, with over 90% of alveoli forming at ages 0–7 years. Bronchopulmonary dysplasia, a major complication of prematurity, occurs when the immature lungs fail to develop due to various damaging factors such as hyperoxia, toxicity, and inflammation. Therefore, the lungs of children are immature and in a critical stage of alveolar development, while adult lungs have completed their development. Consequently, many drugs effective in treating adult lung diseases have limited efficacy in addressing lung diseases in infants and children [72,73].

4. Creation of Neonatal Surgical Rodent Models of CHDs

4.1. Challenges in Constructing Neonatal Surgical Rodent Models of CHDs

The lack of neonatal rodent models for cardiac VO, PO, IPF, and RPF limits our understanding of how hemodynamics regulates postnatal heart and lung development [23,28,30,31]. Consequently, managing CHD primarily relies on surgical intervention, and thus the long-term quality of life for children with complex CHD remains poor [74,75]. The challenges of creating neonatal rodent CHD models are: (1) the size of the neonatal rodent heart is extremely small, with limited operation space; (2) the neonatal anesthesia is ice cooling, limiting the surgical time to no more than 20 min; and (3) cannibalization may account for additional post-surgical mortality in the neonatal surgery. The above three challenges require superb cardiac microsurgical skills.
As the largest pediatric heart center in the world, the heart center of Shanghai Children's Medical Center has about 4,000 open-heart surgeries per year; as a result, surgeons at Shanghai Children's Medical Center are very skillful in cardiac surgery. Thus, in recent years they have successfully developed a series of neonatal CHD models (Figure 3), including models of nACF, nPAB, nPVB, and nTAC [23,28,30,31,76].

4.2. Key Points of Constructing Neonatal Surgical Rodent Models of CHDs

4.2.1. nACF Surgery
The nACF surgery [33] (Figure 3A) includes the following four steps: (1) anesthesia and fixation; (2) abdominal aorta (AA) and inferior vena cava (IVC) exposure; (3) fistula creation, and (4) abdominal closure. There are two key points of nACF surgery: (1) During fistula creation, a mixing of arteriovenous blood in IVC should be observed under a microscope to make sure a successful fistula was created. (2) When exposing the AA and IVC, the small intestine and large intestine should be moved with a cotton swab slowly to prevent bleeding.
4.2.2. nPAB Surgery
The nPAB surgery [30] (Figure 3B) includes the following four steps:(1) anesthesia and fixation; (2) pulmonary artery (PA) exposure; (3) PA banding; and (4) closure of the thoracic cavity. There are two key points of nPAB surgery: (1) The PA should be exposed with a small incision as much as possible to reduce the total time for the thoracotomy surgery, which is critical for the neonatal pups’ recovery from anesthesia. (2) The PA should be separated from its adjacent small vessels with a blunt needle to avoid bleeding.
4.2.3. nTAC Surgery
The nTAC surgery [32] (Figure 3C) includes the following four steps:(1) anesthesia and fixation; (2) ascending aorta exposure; (3) aorta banding; and (4) closure of the thoracic cavity. There are two key points of nTAC surgery: (1) Blunt needles should be used to prevent intraoperative bleeding, which is a primary cause of postoperative mortality. (2) During the surgery, the pericardium must be carefully separated from the aortic surface to expose the aortic site for banding. The pericardium should be kept intact as much as possible to avoid postoperative adhesion.
4.2.4. nPVB Surgery
The nPVB surgery [28] (Figure 3D) includes the following four steps:(1) anesthesia and fixation; (2) pulmonary vein (PV) exposure; (3) PV banding; and (4) closure of the thoracic cavity. There are two key points of nPVB surgery: (1) The right upper and right middle PVs, which are thicker than the other PVs, are selected for banding to replicate PVS. (2) The chest is closed layer by layer to avoid postoperative pneumothorax.
In summary, nACF surgery, which does not require opening the thoracic cavity, is easier to perform than the other three neonatal surgeries. All neonatal surgeries required ice-cooling anesthesia to reduce the operation time as much as possible, which increases the rate of neonatal pup recovery from anesthesia. A blunt needle is required to avoid intraoperative bleeding. For thoracotomy surgery, preventing postoperative adhesions and pneumothorax is a key for the neonatal pups’ long term survival. The surgical videos for each neonatal cardiac surgery can be found at public access websites, summarized in Table 2.

5. Hemodyn

5.1. Cardiomyocyte Proliferation

Promoting cardiomyocyte proliferation is a fundamental method for treating heart failure, which not only improves heart failure caused by myocardial infarction [77,78], but also improves pediatric heart failure caused by CHDs [79,90]. A previous study demonstrated that children with TOF have impaired RV cardiomyocyte proliferation due to reduced expression of epithelial cell transforming 2 (ECT2) [79]. The study also found that beta blockers can promote cardiomyocyte proliferation by enhancing the expression of ECT2 [79]. Thus, beta blockers have been recommended to treat TOF [79]. The New England Journal of Medicine highlighted the study, commenting that the treatment of CHDs may not rely on surgical correction; this study opened a new approach for treating CHDs [80].
However, this study lacked a nPAB model to match the TOF most important clinical feature–RVOT obstruction, which produces RV PO–and made its conclusion based on an increase in the percentage of polyploidic cardiomyocytes in children with TOF [79]. An increased percentage of polyploidic cardiomyocytes could be a consequence of cardiomyocyte proliferation (Figure 4). Increasingly more studies showed that PO promoted neonatal cardiomyocyte proliferation, in both RV and LV [31,81,82,83,84,85]. We also found that PO promoted RV cardiomyocyte proliferation in children with TOF [31]. Therefore, it is inappropriate and unwise to ignore the contribution of PO to cardiomyocyte proliferation when studying pediatric TOF. Moreover, CHD is a polygenic disease, and mutations of ECT2 have rarely been reported in TOF patients [79]. Thus, it is more reasonable to open a new field for CHD treatment focused on abnormal hemodynamics than a single gene modification.
Nevertheless, the effect of PO on promoting proliferation of cardiomyocytes decreases with age, and PO cannot re-induce proliferation of differentiated and mature cardiomyocytes [31]. However, interestingly, VO re-induces proliferation of prepubertal cardiomyocytes in both the LV and RV [22,23], but does not promote proliferation of neonatal cardiomyocytes [86]. In contrast, with heart failure and at an adult stage, pressure unloading promotes cardiomyocyte proliferation [87]. These results show the complex roles of forces generated by abnormal hemodynamics on cardiomyocyte proliferation.
Force is one of the foundations of matter [88,89], and the maintenance of many life phenomena depends on a balance of forces [88,89]. How force regulates cardiac regeneration remains elusive, and perhaps changing a single mechanoreceptor can promote cardiac regeneration. In fact, a recent study demonstrated that Plxnd1 is a necessary and sufficient condition for endothelial cells to sense force for regulating cardiovascular pathophysiology [90]. We also found that Plxnd1 significantly increased in prepubertal cardiomyocytes under VO conditions (Figure 5). The introduction of neonatal ventricular PO and VO models provides a platform for us to explore the regulation of cardiac regeneration by forces, and the role of Plxnd1 may be one of the future directions.

5.2. Cardiomyocyte Maturation

Maturation is the most important event of postnatal cardiomyocyte development in mammals [91,92]. Although the underlying mechanisms of cardiomyocyte maturation are largely unknown, the switch from pediatric to adult hemodynamics is undoubtedly an important contribution [91,92]. Due to the increase in body size, the preload and afterload faced by the adult heart is significantly greater than that of children [91,92]. In other words, it may be the force generated by the increasing preload and afterload that guide the maturation of cardiomyocytes.
The immaturity of cardiomyocytes derived from pluripotent stem cells (iPS-CMs) and their failure to mature in vivo limits their clinical use [93,94]. Therefore, in vitro experiments with various stimuli, including electrical rhythm, force, and 3D culture, were used to promote the maturation of iPS-CMs [93,94]. Although their maturity has increased, there is still a large gap between stimuli-enhanced iPS-CMs and mature adult cardiomyocytes [93,94]. The differences between in vivo and in vitro conditions, as well as an insufficient understanding of force, may account for the limited effect of force on cardiomyocyte maturation in studies.
Recent studies indicated that cardiomyocyte proliferation and maturation are two opposite processes [95,96]. Because VO and PO promote cardiomyocyte proliferation at neonatal or prepubertal stages [23,31], it is not surprising to find that cardiomyocyte maturation was impaired because of VO [22,23]. We also found that VO impeded cardiomyocyte maturation (Figure 6). The purpose of iPS-CM transplantation is to treat patients with heart failure, the hemodynamic characteristic of which is VO. Thus, the finding that VO impedes cardiomyocyte maturation may further deter the transplantation of iPS-CMs into patients with heart failure.
Another issue is whether VO or PO affects cardiomyocyte maturation temporarily or permanently. In other words, when VO or PO is released, can the cardiomyocytes still mature? This is the situation that exists in children with CHD. When the structural defects of the heart of children with CHDs are corrected, will the maturity of their adult cardiomyocytes be affected? Clinical investigations have found that even with perfect anatomic correction in childhood, patients with TOF are still at a high risk of arrhythmia [97], one feature of cardiomyocyte immaturity, suggesting that cardiomyocyte maturation may be permanently impaired.
In summary, some force is helpful for cardiomyocyte maturation in vitro, and force generated by age-increased preload and afterload may guide cardiomyocyte maturation in vivo. However, excessive force due to VO and PO impairs postnatal cardiomyocyte maturation. A key question is how force regulates cardiomyocyte maturation. Does maturation share the same mechanoreceptor(s) used in proliferation? After mechanoreceptor activation, different pathways involved in maturation and proliferation may be subsequently activated. In fact, we found that VO initiated an immune response at neonatal and prepubertal stages in both the RV and LV, including macrophage activation [22,23,86]. Consistently, activation of the mechanoreceptor Plxnd1 in endothelial cells led to expression of macrophage chemokines, which recruited macrophages from the peripheral blood to the heart [90]. These interesting studies are a good foundation for us to understand how force, a basic component of the material world, affects cardiovascular pathophysiology.

5.3. Lung Development

The interplay of the heart and lung profoundly, functionally, and anatomically determine a person’s quality of life [98,99,100]. About half a century ago, an autopsy study revealed a decrease in lung volume and pulmonary dysfunction in patients with RPF-associated CHDs [101]. However, the underlying mechanisms remained elusive until recent nPAB surgery was developed, which showed that RPF caused alveolar dysplasia, angiogenesis impairment, and inflammation [28,29]. RPF also impaired cell–cell communication and axon guidance, two critical events of late alveolar formation [29,102]. Axon guidance is required for the coronavirus infection, which may explain why children with RPF-associated CHDs are relatively insensitive to COVID-19 infection [29,103]. RPF reduces the intravascular pressure and gas exchange rate, which means a reduced force in the vessels of the lung. It is possible that force is the basic cause of RPF-induced pulmonary dysplasia. Interestingly, RPF also induces inflammation [25], similar to that of VO-induced cardiomyocyte proliferation, further suggesting that there may be a force-mediated regulation.
Current bronchopulmonary dysplasia (BPD) animal models for premature infants include models of hyperoxia, pulmonary ventilation, and lipopolysaccharide [104,105], all of which aim to induce inflammation, yet yield poor targets for improving lung development of premature infants [106,107]. This may be because inflammation is not the initiating factor. Complications of premature infants often include PH and PDA [107,108], both of which induce RPF. Thus, RPF may account for premature BPD, and the nPAB model provide a new window into the study of BPD.
In contrast to RPF, IPF, which increases intravascular pressure, leads to pulmonary congestion and thickening of pulmonary small blood vessels, a characteristic of PH, which in turn increases intravascular pressure, and ultimately a vicious circle forms. A nPVB model showed a similar presentation as children with PVS, which included PV thickening, pulmonary small vessels thickening, pulmonary congestion, PH, and RV failure [28]. Consistently, the nACF model causing IPF also showed thickening of pulmonary small blood vessels, but to a lesser extent [33]. The mechanoreceptors in lungs are less studied in lungs than in hearts, including their regulation of force in lungs.

6. Summary and Prospects

Force, a basic component of our world and generated by abnormal hemodynamics in CHDs, produces profound effects on postnatal heart and lung development, which we were previously unaware of due to the lack of neonatal rodent animal models. Nevertheless, we now know that both VO and PO promote prepubertal cardiomyocyte proliferation and impede cardiomyocyte maturation, and we also know that RPF leads to pulmonary dysplasia and IPF leads to thickening of pulmonary blood vessels.

6.1. Clinical Decision Making

VO- and PO-impaired cardiomyocyte maturation are associated with arrhythmias and weakened cardiac systolic function [93,94], suggesting that childhood correction of VO or PO or the promotion of cardiomyocyte maturation may improve adult cardiac performance. However, VO and PO promote prepubertal cardiomyocyte proliferation, which is fundamental to heart failure treatment [96,97], suggesting that VO and PO should be enhanced. Clearly, these two suggestions are contradictory. An in-depth understanding of how force regulates cardiomyocyte proliferation and maturation is a prerequisite for us to precisely regulate proliferation and maturation via VO and PO for improving the quality of life of children with CHD.
RPF and IPF are both detrimental to pulmonary performance, suggesting that it should be corrected as early as possible. If RPF or IPF cannot be corrected, mechanoreceptor blockers, axon guidance molecules, or vessel thickening inhibitors are suggested to be used as early as possible to improve pulmonary performance of children with CHD.

6.2. Limitations and Future Directions

Currently, the neonatal surgical rodent models only help us obtain a very primitive observation, leaving an abundance of unanswered questions: (1) Do mechanoreceptors for VO or PO promote cardiomyocyte proliferation or impede cardiomyocyte maturation? Apart from Plxnd1, other mechanoreceptors have also been revealed. Sdc4 is upregulated, while Itga11 is downregulated in the neonatal PO RV (Figure 7). The expression pattern of neonatal Sdc4 and Itga11 is different from that of adults, in whom both are upregulated [109,110]. How PO or VO regulates cardiomyocyte proliferation and maturation via Plxnd1, Sdc4, and Itga11 might be a future direction of research. Whether there are other mechanoreceptors that play a crucial role in regulating postnatal heart and lung development also needs to be explored. (2). Metabolic reprogramming also occurred under the condition of neonatal PO and VO (Figure 8). Is metabolic reprogramming the cause or result of cardiomyocyte proliferation? How do PO and VO initiate metabolic reprogramming of cardiomyocytes? (3) The chromatin openness of many genes associated with heart and lung development has been changed greatly by PO, VO, IPF, and RPF (data not shown). Epigenetics of hemodynamics should also be a future direction.

Author Contributions

Z.S.; writing—original draft preparation, Y.L.; writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Shanghai Natural Science Foundation (22ZR1479900), the National Natural Science Foundation of China (NSFC) (82270314), and the Innovation Project of the Distinguished Medical Team in Ningbo (2022020405).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Acknowledgments

We thank Debao Li at Children’s Hospital of Fudan University for preparing Figure 1B and Figure 4.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Aird, W.C. Discovery of the cardiovascular system: from Galen to William Harvey. J. Thromb. Haemost. 2011, 9, 118–129. [Google Scholar] [CrossRef]
  2. Bynum, B.; Bynum, H. William Harvey's demonstration rod. Lancet 2015, 386, 1933. [Google Scholar] [CrossRef] [PubMed]
  3. Dewan, S.; Krishnamurthy, A.; Kole, D.; Conca, G.; Kerckhoffs, R.; Puchalski, M.D.; Omens, J.H.; Sun, H.; Nigam, V.; McCulloch, A.D. Model of Human Fetal Growth in Hypoplastic Left Heart Syndrome: Reduced Ventricular Growth Due to Decreased Ventricular Filling and Altered Shape. Front. Pediatr. 2017, 5, 25. [Google Scholar] [CrossRef]
  4. Feit, L.R.; Copel, J.A.; Kleinman, C.S. Foramen ovale size in the normal and abnormal human fetal heart: an indicator of transatrial flow physiology. Ultrasound Obstet. Gynecol. 1991, 1, 313–319. [Google Scholar] [CrossRef]
  5. Tanai, E.; Frantz, S. Pathophysiology of Heart Failure. Compr Physiol. 2015, 6, 187–214. [Google Scholar] [CrossRef] [PubMed]
  6. Thandavarayan, R.A.; Chitturi, K.R.; Guha, A. Pathophysiology of Acute and Chronic Right Heart Failure. Cardiol. Clin. 2020, 38, 149–160. [Google Scholar] [CrossRef] [PubMed]
  7. Nagalingam, R.S.; Chattopadhyaya, S.; Al-Hattab, D.S.; Cheung, D.Y.C.; Schwartz, L.Y.; Jana, S.; Aroutiounova, N.; Ledingham, D.A.; Moffatt, T.L.; Landry, N.M.; et al. Scleraxis and fibrosis in the pressure-overloaded heart. Eur. Hear. J. 2022, 43, 4739–4750. [Google Scholar] [CrossRef]
  8. Burri, P.H. Fetal and Postnatal Development of the Lung. Annu. Rev. Physiol. 1984, 46, 617–628. [Google Scholar] [CrossRef]
  9. Whitsett, J.A.; Wert, S.E.; Trapnell, B.C. Genetic disorders influencing lung formation and function at birth. Hum. Mol. Genet. 2004, 13, R207–R215. [Google Scholar] [CrossRef]
  10. Pedra, C.A.C.; Haddad, J.; Pedra, S.F.; Peirone, A.; Pilla, C.B.; A Marin-Neto, J. Paediatric and congenital heart disease in South America: an overview. Heart 2009, 95, 1385–1392. [Google Scholar] [CrossRef]
  11. Fernandes, P.S.; Magalhães, L.R.; Pezzini, T.R.; Santos, E.F.d.S.; Calderon, M.G. Congenital heart diseases trends in São Paulo State, Brazil: a national live birth data bank analysis. World J. Pediatr. 2022, 18, 472–481. [Google Scholar] [CrossRef] [PubMed]
  12. Galdos, F.X.; Guo, Y.; Paige, S.L.; VanDusen, N.J.; Wu, S.M.; Pu, W.T. ; Cardiac Regeneration: Lessons From Development. Circ. Res. 2017, 120, 941–959. [Google Scholar] [CrossRef] [PubMed]
  13. GBD 2017 Congenital Heart Disease Collaborators. Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc. Health 2020, 4, 185–200. [Google Scholar] [CrossRef] [PubMed]
  14. Tsao, C.W.; Aday, A.W.; Almarzooq, Z.I.; Anderson, C.A.; Arora, P.; Avery, C.L.; Baker-Smith, C.M.; Beaton, A.Z.; Boehme, A.K.; Buxton, A.E.; et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation 2023, 147, E93–E621. [Google Scholar] [CrossRef] [PubMed]
  15. Corporan, D.; Segura, A.; Padala, M. Ultrastructural Adaptation of the Cardiomyocyte to Chronic Mitral Regurgitation. Front. Cardiovasc. Med. 2021, 8. [Google Scholar] [CrossRef] [PubMed]
  16. Offen, S.M.; Baker, D.; Puranik, R.; Celermajer, D.S. Right ventricular volume and its relationship to functional tricuspid regurgitation. IJC Hear. Vasc. 2021, 38, 100940. [Google Scholar] [CrossRef]
  17. Otani, H.; Kagaya, Y.; Yamane, Y.; Chida, M.; Ito, K.; Namiuchi, S.; Shiba, N.; Koseki, Y.; Ninomiya, M.; Ikeda, J.; et al. Long-Term Right Ventricular Volume Overload Increases Myocardial Fluorodeoxyglucose Uptake in the Interventricular Septum in Patients With Atrial Septal Defect. Circulation 2000, 101, 1686–1692. [Google Scholar] [CrossRef]
  18. Goldberg, S.W.; Fisher, S.A.; Wehman, B.; Mehra, M.R. Adults with congenital heart disease and heart transplantation: Optimizing outcomes. J. Hear. Lung Transplant. 2014, 33, 873–877. [Google Scholar] [CrossRef]
  19. Palomo-López, N.; Escalona-Rodríguez, S.; Martín-Villén, L.; Herruzo-Avilés; Hinojosa-Pérez, R. ; Escoresca-Ortega, A.; Porras-López, M.; Corcia-Palomo, Y.; Adsuar-Gómez, A. Transplantation in Congenital Heart Disease: A Challenge. Transplant. Proc. 2020, 52, 577–579. [Google Scholar] [CrossRef]
  20. van der Bom, T.; Winter, M.M.; Bouma, B.J.; Groenink, M.; Vliegen, H.W.; Pieper, P.G.; van Dijk, A.P.; Sieswerda, G.T.; Roos-Hesselink, J.W.; Zwinderman, A.H.; et al. Effect of Valsartan on Systemic Right Ventricular Function: a double-blind, randomized, placebo-controlled pilot trial. Circulation 2013, 127, 322–330. [Google Scholar] [CrossRef]
  21. Mathur, K.; Hsu, D.T.; Lamour, J.M.; Aydin, S.I. Safety of Enalapril in Infants: Data from the Pediatric Heart Network Infant Single Ventricle Trial. J. Pediatr. 2020, 227, 218–223. [Google Scholar] [CrossRef]
  22. Hu, Y.; Li, D.; Zhou, C.; Xiao, Y.; Sun, S.; Jiang, C.; Chen, L.; Liu, J.; Zhang, H.; Li, F.; et al. Molecular Changes in Prepubertal Left Ventricular Development Under Experimental Volume Overload. Front. Cardiovasc. Med. 2022, 9, 850248. [Google Scholar] [CrossRef]
  23. Sun, S.; Hu, Y.; Xiao, Y.; Wang, S.; Jiang, C.; Liu, J.; Zhang, H.; Hong, H.; Li, F.; Ye, L. Postnatal Right Ventricular Developmental Track Changed by Volume Overload. J. Am. Hear. Assoc. 2021, 10, e020854. [Google Scholar] [CrossRef] [PubMed]
  24. Wang, S.; Jiang, C.; Zhao, L.; Sun, S.; Xiao, Y.; Ye, L.; Sun, Q.; Li, J. Metabolic maturation during postnatal right ventricular development switches to heart-contraction regulation due to volume overload. J. Cardiol. 2021, 79, 110–120. [Google Scholar] [CrossRef] [PubMed]
  25. Li, D.-B.; Xu, X.-X.; Hu, Y.-Q.; Cui, Q.; Xiao, Y.-Y.; Sun, S.-J.; Chen, L.-J.; Ye, L.-C.; Sun, Q. Congenital heart disease-associated pulmonary dysplasia and its underlying mechanisms. Am. J. Physiol. Cell. Mol. Physiol. 2023, 324, L89–L101. [Google Scholar] [CrossRef] [PubMed]
  26. Zhou, C.; Li, D.; Cui, Q.; Sun, Q.; Hu, Y.; Xiao, Y.; Jiang, C.; Qiu, L.; Zhang, H.; Ye, L.; et al. Ability of the Right Ventricle to Serve as a Systemic Ventricle in Response to the Volume Overload at the Neonatal Stage. Biology 2022, 11, 1831. [Google Scholar] [CrossRef]
  27. Zhou, C.; Sun, S.; Hu, M.; Xiao, Y.; Yu, X.; Ye, L.; Qiu, L. Downregulated developmental processes in the postnatal right ventricle under the influence of a volume overload. Cell Death Discov. 2021, 7, 1–10. [Google Scholar] [CrossRef] [PubMed]
  28. Li, D.; Qiu, L.; Hong, H.; Chen, H.; Zhao, P.; Xiao, Y.; Zhang, H.; Sun, Q.; Ye, L. A neonatal rat model of pulmonary vein stenosis. Cell Biosci. 2023, 13, 1–11. [Google Scholar] [CrossRef]
  29. Li, D.; Wang, J.; Fang, Y.; Hu, Y.; Xiao, Y.; Cui, Q.; Jiang, C.; Sun, S.; Chen, H.; Ye, L.; et al. Impaired cell–cell communication and axon guidance because of pulmonary hypoperfusion during postnatal alveolar development. Respir. Res. 2023, 24, 1–17. [Google Scholar] [CrossRef]
  30. Wang, S.; Ye, L.; Hong, H.; Tang, C.; Li, M.; Zhang, Z.; Liu, J. A neonatal rat model of increased right ventricular afterload by pulmonary artery banding. J. Thorac. Cardiovasc. Surg. 2017, 154, 1734–1739. [Google Scholar] [CrossRef]
  31. Ye, L.; Wang, S.; Xiao, Y.; Jiang, C.; Huang, Y.; Chen, H.; Zhang, H.; Zhang, H.; Liu, J.; Xu, Z.; et al. Pressure Overload Greatly Promotes Neonatal Right Ventricular Cardiomyocyte Proliferation: A New Model for the Study of Heart Regeneration. J. Am. Heart Assoc. 2020, 9, e015574. [Google Scholar] [CrossRef]
  32. Mohammadi, M.M.; Abouissa, A.; Heineke, J. A surgical mouse model of neonatal pressure overload by transverse aortic constriction. Nat. Protoc. 2020, 16, 775–790. [Google Scholar] [CrossRef] [PubMed]
  33. Sun, S.; Zhu, H.; Wang, S.; Xu, X.; Ye, L. Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model. J. Vis. Exp. 2023, e65372. [Google Scholar] [CrossRef]
  34. McLennan, D.I.; Solano, E.C.R.; Handler, S.S.; Lincoln, J.; Mitchell, M.E.; Kirkpatrick, E.C. Pulmonary Vein Stenosis: Moving From Past Pessimism to Future Optimism. Front. Pediatr. 2021, 9. [Google Scholar] [CrossRef] [PubMed]
  35. Otani, H.; Kagaya, Y.; Yamane, Y.; Chida, M.; Ito, K.; Namiuchi, S.; Shiba, N.; Koseki, Y.; Ninomiya, M.; Ikeda, J.; et al. Long-Term Right Ventricular Volume Overload Increases Myocardial Fluorodeoxyglucose Uptake in the Interventricular Septum in Patients With Atrial Septal Defect. Circulation 2000, 101, 1686–1692. [Google Scholar] [CrossRef] [PubMed]
  36. Abu-Shaweesh, J.M.; Almidani, E. PDA: Does it matter? Int. J. Pediatr. Adolesc. Med. 2019, 7, 11–14. [Google Scholar] [CrossRef]
  37. Hegde, M.; Manjunath, S.C.; Usha, M.K. Isolated Partial Anomalous Pulmonary Venous Connection: Development of Volume Overload and Elevated Estimated Pulmonary Pressure in Adults. J. Clin. Imaging Sci. 2019, 9, 29–6. [Google Scholar] [CrossRef]
  38. Calkoen, E.E.; Hazekamp, M.G.; Blom, N.A.; Elders, B.B.; Groot, A.C.G.-D.; Haak, M.C.; Bartelings, M.M.; Roest, A.A.; Jongbloed, M.R. Atrioventricular septal defect: From embryonic development to long-term follow-up. Int. J. Cardiol. 2015, 202, 784–795. [Google Scholar] [CrossRef]
  39. Grosse-Brockhoff, F.; Loogen, F. Ventricular Septal Defect. Circulation 1968, 38, 13–20. [Google Scholar] [CrossRef]
  40. Hahn, R.T. Tricuspid Regurgitation. New Engl. J. Med. 2023, 388, 1876–1891. [Google Scholar] [CrossRef]
  41. Holst, K.A.; Connolly, H.M.; Dearani, J.A. Ebstein’s Anomaly. Methodist DeBakey Cardiovasc. J. 2019, 15, 138–144. [Google Scholar] [CrossRef]
  42. Bouzas, B.; Kilner, P.J.; Gatzoulis, M.A. Pulmonary regurgitation: not a benign lesion. Eur. Heart J. 2005, 26, 433–439. [Google Scholar] [CrossRef]
  43. Tatewaki, H.; Shiose, A. Pulmonary valve replacement after repaired Tetralogy of Fallot. Gen. Thorac. Cardiovasc. Surg. 2018, 66, 509–515. [Google Scholar] [CrossRef] [PubMed]
  44. Said, S.M.; Mainwaring, R.D.; Ma, M.; Tacy, T.A.; Hanley, F.L. Pulmonary Valve Repair for Patients With Acquired Pulmonary Valve Insufficiency. Ann. Thorac. Surg. 2016, 101, 2294–2301. [Google Scholar] [CrossRef] [PubMed]
  45. Sanz, J.; Sánchez-Quintana, D.; Bossone, E.; Bogaard, H.J.; Naeije, R. Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019, 73, 1463–1482. [Google Scholar] [CrossRef] [PubMed]
  46. Sharma, A.; Stan, M.N. Thyrotoxicosis: Diagnosis and Management. Mayo Clin. Proc. 2019, 94, 1048–1064. [Google Scholar] [CrossRef] [PubMed]
  47. Metcalf, M.K.; Rychik, J. Outcomes in Hypoplastic Left Heart Syndrome. Pediatr. Clin. North Am. 2020, 67, 945–962. [Google Scholar] [CrossRef] [PubMed]
  48. Cohen, M.L.; Spray, T.; Gutierrez, F.; Barzilai, B.; Bauwens, D. Congenital tricuspid valve stenosis with atrial septal defect and left anterior fascicular block. Clin. Cardiol. 1990, 13, 497–499. [Google Scholar] [CrossRef] [PubMed]
  49. Enriquez-Sarano, M.; Akins, C.W.; Vahanian, A. Mitral regurgitation. Lancet 2009, 373, 1382–1394. [Google Scholar] [CrossRef]
  50. Cramariuc, D.; Bahlmann, E.; Gerdts, E. Grading of Aortic Stenosis: Is it More Complicated in Women? Eur. Cardiol. Rev. 2022, 17, 1–5. [Google Scholar] [CrossRef]
  51. Bravo-Jaimes, K.; Prakash, S.K. Genetics in bicuspid aortic valve disease: Where are we? Prog. Cardiovasc. Dis. 2020, 63, 398–406. [Google Scholar] [CrossRef]
  52. Mandras, S.A.; Mehta, H.S.; Vaidya, A. Pulmonary Hypertension: A Brief Guide for Clinicians. Mayo Clin. Proc. 2020, 95, 1978–1988. [Google Scholar] [CrossRef]
  53. Chetan, D.; Mertens, L.L. Challenges in diagnosis and management of coarctation of the aorta. Curr. Opin. Cardiol. 2022, 37, 115–122. [Google Scholar] [CrossRef]
  54. Dickey, J.; Phelan, C. Unrepaired Tetralogy of Fallot in Adulthood. New Engl. J. Med. 2020, 382, e97. [Google Scholar] [CrossRef] [PubMed]
  55. Rali, P.M.; Criner, G.J. Submassive Pulmonary Embolism. Am. J. Respir. Crit. Care Med. 2018, 198, 588–598. [Google Scholar] [CrossRef] [PubMed]
  56. Patel, A.B.; Ratnayaka, K.; Bergersen, L. A review: Percutaneous pulmonary artery stenosis therapy: state-of-the-art and look to the future. Cardiol. Young- 2018, 29, 93–99. [Google Scholar] [CrossRef] [PubMed]
  57. Marchini, F.; Meossi, S.; Passarini, G.; Campo, G.; Pavasini, R. Pulmonary Valve Stenosis: From Diagnosis to Current Management Techniques and Future Prospects. Vasc. Heal. Risk Manag. 2023, ume 19, 379–390. [Google Scholar] [CrossRef]
  58. Maron, B.J.; Maron, M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381, 242–255. [Google Scholar] [CrossRef] [PubMed]
  59. Abassi, H.; Gavotto, A.; Picot, M.C.; Bertet, H.; Matecki, S.; Guillaumont, S.; Moniotte, S.; Auquier, P.; Moreau, J.; Amedro, P. Impaired pulmonary function and its association with clinical outcomes, exercise capacity and quality of life in children with congenital heart disease. Int. J. Cardiol. 2019, 285, 86–92. [Google Scholar] [CrossRef] [PubMed]
  60. Diller, G.-P.; Dimopoulos, K.; Okonko, D.; Li, W.; Babu-Narayan, S.V.; Broberg, C.S.; Johansson, B.; Bouzas, B.; Mullen, M.J.; Poole-Wilson, P.A.; et al. Exercise Intolerance in Adult Congenital Heart Disease: comparative severity, correlates, and prognostic implication. Circulation 2005, 112, 828–835. [Google Scholar] [CrossRef]
  61. Talman, V.; Teppo, J.; Pöhö, P.; Movahedi, P.; Vaikkinen, A.; Karhu, S.T.; Trošt, K.; Suvitaival, T.; Heikkonen, J.; Pahikkala, T.; et al. Molecular Atlas of Postnatal Mouse Heart Development. J. Am. Hear. Assoc. 2018, 7, e010378. [Google Scholar] [CrossRef] [PubMed]
  62. Guo, Y.; Pu, W.T. Cardiomyocyte Maturation: New Phase in Development. Circ. Res. 2020, 126, 1086–1106. [Google Scholar] [CrossRef] [PubMed]
  63. Papanicolaou, K.N.; Kikuchi, R.; Ngoh, G.A.; Coughlan, K.A.; Dominguez, I.; Stanley, W.C.; Walsh, K.; Y, G.; W, P.; Q, Z.; et al. Mitofusins 1 and 2 Are Essential for Postnatal Metabolic Remodeling in Heart. Circ. Res. 2012, 111, 1012–1026. [Google Scholar] [CrossRef] [PubMed]
  64. Piquereau, J.; Novotova, M.; Fortin, D.; Garnier, A.; Ventura-Clapier, R.; Veksler, V.; Joubert, F. Postnatal development of mouse heart: formation of energetic microdomains. J. Physiol. 2010, 588, 2443–2454. [Google Scholar] [CrossRef] [PubMed]
  65. Reynolds, J.O.; Chiang, D.Y.; Wang, W.; Beavers, D.L.; Dixit, S.S.; Skapura, D.G.; Landstrom, A.P.; Song, L.-S.; Ackerman, M.J.; Wehrens, X.H. Junctophilin-2 is necessary for T-tubule maturation during mouse heart development. Cardiovasc. Res. 2013, 100, 44–53. [Google Scholar] [CrossRef] [PubMed]
  66. Hong, T.; Yang, H.; Zhang, S.-S.; Cho, H.C.; Kalashnikova, M.; Sun, B.; Zhang, H.; Bhargava, A.; Grabe, M.; Olgin, J.; et al. Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia. Nat. Med. 2014, 20, 624–632. [Google Scholar] [CrossRef]
  67. Ong, L.P.; Bargehr, J.; Knight-Schrijver, V.R.; Lee, J.; Colzani, M.; Bayraktar, S.; Bernard, W.G.; Marchiano, S.; Bertero, A.; Murry, C.E.; et al. Epicardially secreted fibronectin drives cardiomyocyte maturation in 3D-engineered heart tissues. Stem Cell Rep. Epub ahead of print. 2023, 18, 936–951. [Google Scholar] [CrossRef]
  68. Thébaud, B.; Goss, K.N.; Laughon, M.; Whitsett, J.A.; Abman, S.H.; Steinhorn, R.H.; Aschner, J.L.; Davis, P.G.; McGrath-Morrow, S.A.; Soll, R.F.; et al. Bronchopulmonary dysplasia. Nat. Rev. Dis. Prim. 2019, 5, 1–23. [Google Scholar] [CrossRef]
  69. Salaets, T.; Aertgeerts, M.; Gie, A.; Vignero, J.; de Winter, D.; Regin, Y.; Jimenez, J.; Velde, G.V.; Allegaert, K.; Deprest, J.; et al. Preterm birth impairs postnatal lung development in the neonatal rabbit model. Respir. Res. 2020, 21, 1–13. [Google Scholar] [CrossRef]
  70. Jobe, A.H. Animal Models, Learning Lessons to Prevent and Treat Neonatal Chronic Lung Disease. Front. Med. 2015, 2, 49. [Google Scholar] [CrossRef]
  71. Zepp, J.A.; Morley, M.P.; Loebel, C.; Kremp, M.M.; Chaudhry, F.N.; Basil, M.C.; Leach, J.P.; Liberti, D.C.; Niethamer, T.K.; Ying, Y.; et al. Genomic, epigenomic, and biophysical cues controlling the emergence of the lung alveolus. Science 2021, 371, 1124. [Google Scholar] [CrossRef] [PubMed]
  72. Frank, B.S.; Ivy, D.D. Pediatric Pulmonary Arterial Hypertension. Pediatr. Clin. North Am. 2020, 67, 903–921. [Google Scholar] [CrossRef] [PubMed]
  73. Ivy, D.D.; Abman, S.H.; Barst, R.J.; Berger, R.M.; Bonnet, D.; Fleming, T.R.; Haworth, S.G.; Raj, J.U.; Rosenzweig, E.B.; Neick, I.S.; et al. Pediatric Pulmonary Hypertension. J. Am. Coll. Cardiol. 2013, 62, D117–D126. [Google Scholar] [CrossRef] [PubMed]
  74. Marino, B.S.M.; Cassedy, A.; Brown, K.L.; Franklin, R.; Gaynor, J.W.; Cvetkovic, M.; Laker, S.R.; Levinson, K.; MacGloin, H.; Mahony, L.; et al. Long-Term Quality of Life in Congenital Heart Disease Surgical Survivors: Multicenter Retrospective Study of Surgical and ICU Explanatory Factors. Pediatr. Crit. Care Med. 2023, 24, 391–398. [Google Scholar] [CrossRef] [PubMed]
  75. Wang, T.; Chen, L.; Yang, T.; Huang, P.; Wang, L.; Zhao, L.; Zhang, S.; Ye, Z.; Chen, L.; Zheng, Z.; et al. Congenital Heart Disease and Risk of Cardiovascular Disease: A Meta-Analysis of Cohort Studies. J. Am. Hear. Assoc. 2019, 8, e012030. [Google Scholar] [CrossRef]
  76. Shi, B.; Zhang, X.; Song, Z.; Dai, Z.; Luo, K.; Chen, B.; Zhou, Z.; Cui, Y.; Feng, B.; Zhu, Z.; et al. Targeting gut microbiota–derived kynurenine to predict and protect the remodeling of the pressure-overloaded young heart. Sci. Adv. 2023, 9, eadg7417. [Google Scholar] [CrossRef]
  77. Du, J.; Zheng, L.; Gao, P.; Yang, H.; Yang, W.-J.; Guo, F.; Liang, R.; Feng, M.; Wang, Z.; Zhang, Z.; et al. A small-molecule cocktail promotes mammalian cardiomyocyte proliferation and heart regeneration. Cell Stem Cell 2022, 29, 545–558. [Google Scholar] [CrossRef]
  78. Wu, Y.; Zhou, L.; Liu, H.; Duan, R.; Zhou, H.; Zhang, F.; He, X.; Lu, D.; Xiong, K.; Xiong, M.; et al. LRP6 downregulation promotes cardiomyocyte proliferation and heart regeneration. Cell Res. 2020, 31, 450–462. [Google Scholar] [CrossRef]
  79. Liu, H.; Zhang, C.-H.; Ammanamanchi, N.; Suresh, S.; Lewarchik, C.; Rao, K.; Uys, G.M.; Han, L.; Abrial, M.; Yimlamai, D.; et al. Control of cytokinesis by β-adrenergic receptors indicates an approach for regulating cardiomyocyte endowment. Sci. Transl. Med. 2019, 11. [Google Scholar] [CrossRef] [PubMed]
  80. Yutzey, K.E. Cytokinesis, Beta-Blockers, and Congenital Heart Disease. New Engl. J. Med. 2020, 382, 291–293. [Google Scholar] [CrossRef] [PubMed]
  81. Gu, J.; Chen, X.; Jin, Y.; Liu, M.; Xu, Q.; Liu, X.; Luo, Z.; Ling, S.; Liu, N.; Liu, S. A Neonatal Mouse Model for Pressure Overload: Myocardial Response Corresponds to Severity. Front. Cardiovasc. Med. 2021, 8. [Google Scholar] [CrossRef]
  82. Mohammadi, M.M.; Abouissa, A.; Isyatul, A.; Xie, Y.; Cordero, J.; Shirvani, A.; Gigina, A.; Engelhardt, M.; Trogisch, F.A.; Geffers, R.; et al. Induction of cardiomyocyte proliferation and angiogenesis protects neonatal mice from pressure overload–associated maladaptation. J. Clin. Investig. 2019, 4. [Google Scholar] [CrossRef]
  83. Ding, X.; Wang, S.; Wang, Y.; Yang, J.; Bao, N.; Liu, J.; Zhang, Z. Neonatal Heart Responds to Pressure Overload With Differential Alterations in Various Cardiomyocyte Maturation Programs That Accommodate Simultaneous Hypertrophy and Hyperplasia. Front. Cell Dev. Biol. 2020, 8. [Google Scholar] [CrossRef]
  84. Liu, X.; Pu, W.; He, L.; Li, Y.; Zhao, H.; Li, Y.; Liu, K.; Huang, X.; Weng, W.; Wang, Q.-D.; et al. Cell proliferation fate mapping reveals regional cardiomyocyte cell-cycle activity in subendocardial muscle of left ventricle. Nat. Commun. 2021, 12, 5784. [Google Scholar] [CrossRef]
  85. Bossers, G.P.; Günthel, M.; van der Feen, D.E.; Hagdorn, Q.A.; Koop, A.-M.C.; van Duijvenboden, K.; Barnett, P.; Borgdorff, M.A.; Christoffels, V.M.; Silljé, H.H.; et al. Neuregulin-1 enhances cell-cycle activity, delays cardiac fibrosis, and improves cardiac performance in rat pups with right ventricular pressure load. J. Thorac. Cardiovasc. Surg. 2022, 164, e493–e510. [Google Scholar] [CrossRef]
  86. Cui, Q.; Sun, S.; Zhu, H.; Xiao, Y.; Jiang, C.; Zhang, H.; Liu, J.; Ye, L.; Shen, J. Volume Overload Initiates an Immune Response in the Right Ventricle at the Neonatal Stage. Front. Cardiovasc. Med. 2021, 8. [Google Scholar] [CrossRef]
  87. Canseco, D.C.; Kimura, W.; Garg, S.; Mukherjee, S.; Bhattacharya, S.; Abdisalaam, S.; Das, S.; Asaithamby, A.; Mammen, P.P.; Sadek, H.A. Human Ventricular Unloading Induces Cardiomyocyte Proliferation. J. Am. Coll. Cardiol. 2015, 65, 892–900. [Google Scholar] [CrossRef]
  88. Davoodianidalik, M.; Punzmann, H.; Kellay, H.; Xia, H.; Shats, M.; Francois, N. Fluctuation-Induced Interaction in Turbulent Flows. Phys. Rev. Lett. 2022, 128, 024503. [Google Scholar] [CrossRef] [PubMed]
  89. Butcher, D.T.; Alliston, T.; Weaver, V.M. A tense situation: forcing tumour progression. Nat. Cancer 2009, 9, 108–122. [Google Scholar] [CrossRef] [PubMed]
  90. Mehta, V.; Pang, K.-L.; Rozbesky, D.; Nather, K.; Keen, A.; Lachowski, D.; Kong, Y.; Karia, D.; Ameismeier, M.; Huang, J.; et al. The guidance receptor plexin D1 is a mechanosensor in endothelial cells. Nature 2020, 578, 290–295. [Google Scholar] [CrossRef] [PubMed]
  91. Guo, Y.; Pu, W.T. Cardiomyocyte Maturation: New Phase in Development. Circ. Res. 2020, 126, 1086–1106. [Google Scholar] [CrossRef]
  92. Karbassi, E.; Fenix, A.; Marchiano, S.; Muraoka, N.; Nakamura, K.; Yang, X.; Murry, C.E. Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat. Rev. Cardiol. 2020, 17, 341–359. [Google Scholar] [CrossRef] [PubMed]
  93. Wang, Y.; Yu, M.; Hao, K.; Lei, W.; Tang, M.; Hu, S. Cardiomyocyte Maturation–the Road is not Obstructed. Stem Cell Rev. Rep. 2022, 18, 2966–2981. [Google Scholar] [CrossRef]
  94. Kannan, S.; Kwon, C. Regulation of cardiomyocyte maturation during critical perinatal window. J. Physiol. 2019, 598, 2941–2956. [Google Scholar] [CrossRef]
  95. Zhao, M.-T.; Ye, S.; Su, J.; Garg, V. Cardiomyocyte Proliferation and Maturation: Two Sides of the Same Coin for Heart Regeneration. Front. Cell Dev. Biol. 2020, 8, 594226. [Google Scholar] [CrossRef] [PubMed]
  96. Wang, W.E.; Li, L.; Xia, X.; Fu, W.; Liao, Q.; Lan, C.; Yang, D.; Chen, H.; Yue, R.; Zeng, C.; et al. Dedifferentiation, Proliferation, and Redifferentiation of Adult Mammalian Cardiomyocytes After Ischemic Injury. Circulation 2017, 136, 834–848. [Google Scholar] [CrossRef] [PubMed]
  97. Krieger, E.V.; Zeppenfeld, K.; DeWitt, E.S.; Duarte, V.E.; Egbe, A.C.; Haeffele, C.; Lin, K.Y.; Robinson, M.R.; Sillman, C.; Upadhyay, S.; et al. Arrhythmias in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association. Circ. Arrhythmia Electrophysiol. 2022, 15, 776–791. [Google Scholar] [CrossRef]
  98. Badagliacca, R.; Papa, S.; Valli, G.; Pezzuto, B.; Poscia, R.; Reali, M.; Manzi, G.; Giannetta, E.; Berardi, D.; Sciomer, S.; et al. Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2017, 49, 1601419. [Google Scholar] [CrossRef]
  99. Van Aerde, N.; Meersseman, P.; Debaveye, Y.; Wilmer, A.; Casaer, M.P.; Gunst, J.; Wauters, J.; Wouters, P.J.; Goetschalckx, K.; Gosselink, R.; et al. Aerobic exercise capacity in long-term survivors of critical illness: secondary analysis of the post-EPaNIC follow-up study. Intensiv. Care Med. 2021, 47, 1462–1471. [Google Scholar] [CrossRef]
  100. McKenzie, D.C. Respiratory physiology: adaptations to high-level exercise. Br. J. Sports Med. 2012, 46, 381–384. [Google Scholar] [CrossRef]
  101. De Troyer, A.; Yernault, J.C.; Englert, M. Lung hypoplasia in congenital pulmonary valve stenosis. Circulation 1977, 56, 647–651. [Google Scholar] [CrossRef] [PubMed]
  102. Beauchemin, K.J.; Wells, J.M.; Kho, A.T.; Philip, V.M.; Kamir, D.; Kohane, I.S.; Graber, J.H.; Bult, C.J. Temporal dynamics of the developing lung transcriptome in three common inbred strains of laboratory mice reveals multiple stages of postnatal alveolar development. PeerJ 2016, 4, e2318. [Google Scholar] [CrossRef]
  103. Cantuti-Castelvetri, L.; Ojha, R.; Pedro, L.D.; Djannatian, M.; Franz, J.; Kuivanen, S.; Van Der Meer, F.; Kallio, K.; Kaya, T.; Anastasina, M.; et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 2020, 370, 856–860. [Google Scholar] [CrossRef] [PubMed]
  104. Namba, F. An experimental animal model of bronchopulmonary dysplasia: Secondary publication. Pediatr. Int. 2021, 63, 504–509. [Google Scholar] [CrossRef] [PubMed]
  105. Jobe, A.H. Animal Models, Learning Lessons to Prevent and Treat Neonatal Chronic Lung Disease. Front. Med. 2015, 2, 49. [Google Scholar] [CrossRef] [PubMed]
  106. Lee, J.W.; Davis, J.M. Future applications of antioxidants in premature infants. Curr. Opin. Pediatr. 2011, 23, 161–166. [Google Scholar] [CrossRef]
  107. Thébaud, B.; Goss, K.N.; Laughon, M.; Whitsett, J.A.; Abman, S.H.; Steinhorn, R.H.; Aschner, J.L.; Davis, P.G.; McGrath-Morrow, S.A.; Soll, R.F.; et al. Bronchopulmonary dysplasia. Nat. Rev. Dis. Prim. 2019, 5, 1–23. [Google Scholar] [CrossRef]
  108. Mourani, P.M.; Sontag, M.K.; Younoszai, A.; Miller, J.I.; Kinsella, J.P.; Baker, C.D.; Poindexter, B.B.; Ingram, D.A.; Abman, S.H. Early Pulmonary Vascular Disease in Preterm Infants at Risk for Bronchopulmonary Dysplasia. Am. J. Respir. Crit. Care Med. 2015, 191, 87–95. [Google Scholar] [CrossRef]
  109. Herum, K.M.; Lunde, I.G.; Skrbic, B.; Louch, W.E.; Hasic, A.; Boye, S.; Unger, A.; Brorson, S.-H.; Sjaastad, I.; Tønnessen, T.; et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. Cardiovasc. Res. 2015, 106, 217–226. [Google Scholar] [CrossRef] [PubMed]
  110. Yu, C.; Qiu, M.; Zhang, Z.; Song, X.; Du, H.; Peng, H.; Li, Q.; Yang, L.; Xiong, X.; Xia, B.; et al. Transcriptome sequencing reveals genes involved in cadmium-triggered oxidative stress in the chicken heart. Poult. Sci. 2021, 100, 100932. [Google Scholar] [CrossRef] [PubMed]
Preprints 99711 g001
Figure 1. Illustration of three main characteristics that immature cardiomyocytes require for development. (A) Neonatal and adult cardiomyocytes have differences in sarcomere, metabolism, and electrophysiological functions. (B) Three main characteristics that immature cardiomyocytes need to develop, and the presumed key time points in rodents.
Figure 1. Illustration of three main characteristics that immature cardiomyocytes require for development. (A) Neonatal and adult cardiomyocytes have differences in sarcomere, metabolism, and electrophysiological functions. (B) Three main characteristics that immature cardiomyocytes need to develop, and the presumed key time points in rodents.
Preprints 99711 g001
Preprints 99711 g002
Figure 2. Five developmental stages of human lungs. Note that 90% of alveoli are formed at ages 0–7 years.
Figure 2. Five developmental stages of human lungs. Note that 90% of alveoli are formed at ages 0–7 years.
Preprints 99711 g002
Preprints 99711 g003
Figure 3. Neonatal surgical rodent models of CHDs. (A) nACF produces RA VO, RV VO, LA VO, LV VO, and IPF. (B) nPAB produces RV PO and RPF. (C) nTAC produces LV PO. (D) nPVB produces PVS and IPF. IVC: inferior vena cava; PA: pulmonary artery; DA: ductus arteriosus; Ao: aorta; RPA: right pulmonary artery; PV: pulmonary vein; SVC: superior vena cava; RA: right atrium; MPA: main pulmonary artery. Figure 3A was adopted from the JAHA journal (Sun S, et al. J Am Heart Assoc. 2021 Aug 17;10(16):e020854) under a Creative Commons Attribution-NonCommercial-NoDerivs License; Figure 3B was adopted from the JTCVS journal (Wang S, et al. J Thorac Cardiovasc Surg. 2017 Nov;154(5):1734-1739) with the permission of the publisher.
Figure 3. Neonatal surgical rodent models of CHDs. (A) nACF produces RA VO, RV VO, LA VO, LV VO, and IPF. (B) nPAB produces RV PO and RPF. (C) nTAC produces LV PO. (D) nPVB produces PVS and IPF. IVC: inferior vena cava; PA: pulmonary artery; DA: ductus arteriosus; Ao: aorta; RPA: right pulmonary artery; PV: pulmonary vein; SVC: superior vena cava; RA: right atrium; MPA: main pulmonary artery. Figure 3A was adopted from the JAHA journal (Sun S, et al. J Am Heart Assoc. 2021 Aug 17;10(16):e020854) under a Creative Commons Attribution-NonCommercial-NoDerivs License; Figure 3B was adopted from the JTCVS journal (Wang S, et al. J Thorac Cardiovasc Surg. 2017 Nov;154(5):1734-1739) with the permission of the publisher.
Preprints 99711 g003
Preprints 99711 g004
Figure 4. Possible mechanism of an increased percentage of polyploid cardiomyocytes in TOF children. (A) Four clinical features of TOF: RVOT obstruction, ventricular septal defect, thickened RV, and aortic riding, the most important of which is RVOT obstruction, which leads to RV PO and RV failure. (B) Illustration of increased binuclear cardiomyocytes generated in TOF patients. Greater numbers of binuclear cardiomyocytes do not indicate failure of cytokinesis. For example, in the beginning of a study, if both the control group and TOF group had 80 mononucleated and 20 binucleated cardiomyocytes (CMs), the proportion of binucleated CMs was 20%. Under PO conditions, both mononucleated and binucleated CMs in the TOF group increased by 10, and the proportion of binucleated CMs was 25%. Therefore, an increase in the proportion of binucleated CMs does not necessarily mean impaired cytokinesis and proliferation.
Figure 4. Possible mechanism of an increased percentage of polyploid cardiomyocytes in TOF children. (A) Four clinical features of TOF: RVOT obstruction, ventricular septal defect, thickened RV, and aortic riding, the most important of which is RVOT obstruction, which leads to RV PO and RV failure. (B) Illustration of increased binuclear cardiomyocytes generated in TOF patients. Greater numbers of binuclear cardiomyocytes do not indicate failure of cytokinesis. For example, in the beginning of a study, if both the control group and TOF group had 80 mononucleated and 20 binucleated cardiomyocytes (CMs), the proportion of binucleated CMs was 20%. Under PO conditions, both mononucleated and binucleated CMs in the TOF group increased by 10, and the proportion of binucleated CMs was 25%. Therefore, an increase in the proportion of binucleated CMs does not necessarily mean impaired cytokinesis and proliferation.
Preprints 99711 g004
Preprints 99711 g005
Figure 5. Plxnd1 significantly increased in prepubertal cardiomyocytes under VO. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE157396.
Figure 5. Plxnd1 significantly increased in prepubertal cardiomyocytes under VO. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE157396.
Preprints 99711 g005
Preprints 99711 g006
Figure 6. VO impeded cardiomyocyte maturation. (A) Enrichment of sarcomere- and T-tubule- associated terms in the Gene Ontology (GO) analysis of downregulated genes under VO. (B) Heat map of representative sarcomere and T-tubule genes. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE186968.
Figure 6. VO impeded cardiomyocyte maturation. (A) Enrichment of sarcomere- and T-tubule- associated terms in the Gene Ontology (GO) analysis of downregulated genes under VO. (B) Heat map of representative sarcomere and T-tubule genes. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE186968.
Preprints 99711 g006
Preprints 99711 g007
Figure 7. Sdc4 is upregulated and Itga11 is downregulated in the neonatal PO RV. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE139561.
Figure 7. Sdc4 is upregulated and Itga11 is downregulated in the neonatal PO RV. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE139561.
Preprints 99711 g007
Preprints 99711 g008
Figure 8. Metabolic reprogramming occurred with neonatal PO or VO. (A) Principal component analysis of RV metabolic reprogramming under neonatal PO. (B) Heat map of metabolites under neonatal PO. Note that glycolysis was upregulated, while the TCA cycle was downregulated under PO. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE139561.
Figure 8. Metabolic reprogramming occurred with neonatal PO or VO. (A) Principal component analysis of RV metabolic reprogramming under neonatal PO. (B) Heat map of metabolites under neonatal PO. Note that glycolysis was upregulated, while the TCA cycle was downregulated under PO. Raw data have been deposited in NCBI’s Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo) with accession number GSE139561.
Preprints 99711 g008
Table 1. Abnormal hemodynamic classification and their corresponding congenital heart diseases(CHDs).
Table 1. Abnormal hemodynamic classification and their corresponding congenital heart diseases(CHDs).
Abnormal hemodynamic classification RV VO LV VO RV PO LV PO
CHD ASD、PDA、PAPVD、VSD、TR、EA、PVI、TOF、AVSD、PAH ASD+TS/RVOT、MR、MVI、AR、BAV PVS、VSD、PDA、PAH、MS、AS、TOF、IAA、CAA、PAS、PVS BAV、IAA、CAA、MS、AS、HCM
Table 2. Neonatal cardiac surgery teaching videos.
Table 2. Neonatal cardiac surgery teaching videos.
Surgery Website ref
nACF https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.020854 23
nTAC https://www.nature.com/articles/s41596-020-00434-9 32
nPAB https://www.jtcvs.org/article/S0022-5223(17)31192-3/fulltext#supplementaryMaterial 30
nPVB https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-023-01058-8 28
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated